Compound: epoxomicin
SMILES: O=C(N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)[C@@]1(OC1)C)CC(C)C)[C@H](O)C)[C@H](CC)C)[C@@H](N(C(=O)C)C)[C@H](CC)C
InChIKey: DOGIDQKFVLKMLQ-JTHVHQAWSA-N
Synonyms: epoxomicin, 134381-21-8, BU-4061T, EPOXOMYCIN, Y0900I3U8U, (2S,3S)-2-[[(2S,3S)-2-[acetyl(methyl)amino]-3-methylpentanoyl]amino]-N-[(2S,3R)-3-hydroxy-1-[[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]amino]-1-oxobutan-2-yl]-3-methylpentanamide, DTXSID5044073, CHEBI:42265, L-threoninamide, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyl-2-oxiranyl)carbonyl)butyl)-, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-((1S)-3-methyl-1-(((2R)-2-methyl-2-oxiranyl)carbonyl)butyl)-L-threoninamide, (2S,3S)-2-(((2S,3S)-2-(acetyl(methyl)amino)-3-methylpentanoyl)amino)-N-((2S,3R)-3-hydroxy-1-(((2S)-4-methyl-1-((2R)-2-methyloxiran-2-yl)-1-oxopentan-2-yl)amino)-1-oxobutan-2-yl)-3-methylpentanamide, RefChem:137356, DTXCID80819894, MFCD03791061, C28H50N4O7, N-acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-threoninamide, BU 4061T, UNII-Y0900I3U8U, Epoxomicin solution, EPOXOMICIN [MI], SCHEMBL73907, orb1300427, DOGIDQKFVLKMLQ-JTHVHQAWSA-N, GLXC-07975, EX-A1663, IEP-4381, JFA38121, AKOS025396426, Epoxomicin, >=95% (HPLC), solid, CS-3998, NCGC00389337-01, NCGC00389337-02, NCGC00485955-01, (2S,3S)-N-[(1S,2R)-2-hydroxy-1-{[(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl]carbamoyl}propyl]-3-methyl-2-[(2S,3S)-3-methyl-2-(N-methylacetamido)pentanamido]pentanamide, DA-63239, HY-13821, MS-30118, N-Acetyl-N-methyl-L-isoleucyl-L-isoleucyl-N-(3-methyl-1-((2-methyloxiranyl)carbonyl)butyl)-L-threoninamide, Q5383826, (2R,3S)-2-[acetyl(methyl)amino]-N-[(2S,3S)-1-{[(2S,3R)-3-hydroxy-1-({(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}amino)-1-oxobutan-2-yl]amino}-3-methyl-1-oxopentan-2-yl]-3-methylpentanamide, (2S,3S)-2-[[(2S,3S)-2-[acetyl(methyl)amino]-3-methyl-pentanoyl]amino]-N-[(1S,2R)-2-hydroxy-1-[[(1S)-3-methyl-1-[(2R)-2-methyloxirane-2-carbonyl]butyl]carbamoyl]propyl]-3-methyl-pentanamide
Theoretical properties:
molecular_formula: C28H50N4O7
molecular_weight: 554.7 g/mol
exact_mass: 554.36794995 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 4
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 16
heavy_atom_count: 39
topological_polar_surface_area: 157 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Epoxomicin is a tripeptide consisting of an Ile-Ile-Thr-NH2 sequence N-substituted on the threonamide amidic nitrogen with a (2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl group and with acetyl and methyl groups on the nitrogen of the isoleucine residue distal to the threonamide; a naturally occurring selective proteasome inhibitor with anti-inflammatory activity. It has a role as a proteasome inhibitor. It is a member of morpholines and a tripeptide.
chebi: A tripeptide consisting of an Ile-Ile-Thr-NH<small><sub>2</sub></small> sequence N-substituted on the threonamide amidic nitrogen with a (2<i>S</i>)-4-methyl-1-[(2<i>R</i>)-2-methyloxiran-2-yl]-1-oxopentan-2-yl group and with acetyl and methyl groups on the nitrogen of the isoleucine residue distal to the threonamide; a naturally occurring selective proteasome inhibitor with anti-inflammatory activity.
chembl: EPOXOMYCIN is a protein listed in the ChEMBL database but has not progressed to an approved clinical phase.
wikipedia: Epoxomicin is a naturally occurring selective proteasome inhibitor with anti-inflammatory activity. It was originally discovered in 1992.  Injected, it can induce Parkinson's-like symptoms in rats.
Derivatives of epoxomicin include carfilzomib.